NCT00061906View on ClinicalTrials.gov

Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Head and Neck Cancer
Interventions
DRUG

celecoxib

Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.

Trial Locations (2)

43210-1240

Ohio State University Comrehensive Cancer Center, Columbus

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00061906 - Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter